Apollomics is cutting jobs and ending its lung cancer study because it doesn't have enough money.

APLM · Apollomics Inc.

The AI's read

That leaves the company without its U.S. team and removes a key research effort. The earlier blood-cancer study also failed to show a survival benefit compared with chemotherapy alone. With a vote on liquidation scheduled, the report gives no sign of business improvement to counter these setbacks.